Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives $39.75 Consensus Price Target from Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have received a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $39.75.

A number of analysts have issued reports on the stock. HC Wainwright boosted their price objective on shares of Genmab A/S from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, November 10th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, September 23rd. Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Truist Financial reaffirmed a “buy” rating and issued a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Finally, Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC lifted its holdings in shares of Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after acquiring an additional 1,143 shares during the period. Brown Brothers Harriman & Co. lifted its stake in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the last quarter. Community Bank N.A. bought a new stake in Genmab A/S during the third quarter worth $47,000. Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 136.3% in the 3rd quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock valued at $47,000 after purchasing an additional 883 shares in the last quarter. Finally, Headlands Technologies LLC increased its stake in shares of Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after purchasing an additional 1,464 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Down 0.9%

Shares of GMAB stock opened at $31.74 on Friday. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $33.65. The company has a market capitalization of $20.39 billion, a PE ratio of 13.51, a price-to-earnings-growth ratio of 1.65 and a beta of 0.90. The firm has a 50 day moving average price of $30.84 and a two-hundred day moving average price of $25.98.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $975.40 million. As a group, research analysts expect that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.